Volume 23, No 2, Feb 2013
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 23 Issue 2, February 2013: 179-181
RESEARCH HIGHLIGHTS
Microenvironment-mediated resistance to anticancer therapies
Oakley C Olson1,2 and Johanna A Joyce1
1Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
2Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
Correspondence: Johanna A Joyce(joycej@mskcc.org)
Resistance to molecularly targeted therapies can result from genomic alterations in the tumor cells that reactivate oncogenic signaling. Less is known of tumor cell-extrinsic mechanisms of resistance to targeted therapies. Two recent studies have identified HGF as a soluble factor capable of mediating resistance to BRAF and HER2 inhibitors in a paracrine manner. These new findings suggest an important role for the tumor microenvironment in mediating resistance to molecularly targeted therapies.
Cell Research (2013) 23:179–181; doi:10.1038/cr.2012.123; published online 4 September 2012
FULL TEXT | PDF
Browse 1895
